These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
332 related articles for article (PubMed ID: 27061921)
1. Nonrandomized comparison of neurofibromatosis type 1 and non-neurofibromatosis type 1 children who received carboplatin and vincristine for progressive low-grade glioma: A report from the Children's Oncology Group. Ater JL; Xia C; Mazewski CM; Booth TN; Freyer DR; Packer RJ; Sposto R; Vezina G; Pollack IF Cancer; 2016 Jun; 122(12):1928-36. PubMed ID: 27061921 [TBL] [Abstract][Full Text] [Related]
2. Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children's Oncology Group. Ater JL; Zhou T; Holmes E; Mazewski CM; Booth TN; Freyer DR; Lazarus KH; Packer RJ; Prados M; Sposto R; Vezina G; Wisoff JH; Pollack IF J Clin Oncol; 2012 Jul; 30(21):2641-7. PubMed ID: 22665535 [TBL] [Abstract][Full Text] [Related]
3. Low grade chiasmatic-hypothalamic glioma-carboplatin and vincristin chemotherapy effectively defers radiotherapy within a comprehensive treatment strategy -- report from the multicenter treatment study for children and adolescents with a low grade glioma -- HIT-LGG 1996 -- of the Society of Pediatric Oncology and Hematology (GPOH). Gnekow AK; Kortmann RD; Pietsch T; Emser A Klin Padiatr; 2004; 216(6):331-42. PubMed ID: 15565548 [TBL] [Abstract][Full Text] [Related]
4. Phase II study of 6-thioguanine, procarbazine, dibromodulcitol, lomustine, and vincristine chemotherapy with radiotherapy for treating malignant glioma in children. Levin VA; Lamborn K; Wara W; Davis R; Edwards M; Rabbitt J; Malec M; Prados MD Neuro Oncol; 2000 Jan; 2(1):22-8. PubMed ID: 11302250 [TBL] [Abstract][Full Text] [Related]
5. Natural history and outcome of optic pathway gliomas in children. Nicolin G; Parkin P; Mabbott D; Hargrave D; Bartels U; Tabori U; Rutka J; Buncic JR; Bouffet E Pediatr Blood Cancer; 2009 Dec; 53(7):1231-7. PubMed ID: 19621457 [TBL] [Abstract][Full Text] [Related]
6. Chemotherapy for progressive low-grade gliomas in children older than ten years: the Dana-Farber experience. Heath JA; Turner CD; Poussaint TY; Scott RM; Goumnerova L; Kieran MW Pediatr Hematol Oncol; 2003; 20(7):497-504. PubMed ID: 12959854 [TBL] [Abstract][Full Text] [Related]
7. Long-term follow-up of the multicenter, multidisciplinary treatment study HIT-LGG-1996 for low-grade glioma in children and adolescents of the German Speaking Society of Pediatric Oncology and Hematology. Gnekow AK; Falkenstein F; von Hornstein S; Zwiener I; Berkefeld S; Bison B; Warmuth-Metz M; Driever PH; Soerensen N; Kortmann RD; Pietsch T; Faldum A Neuro Oncol; 2012 Oct; 14(10):1265-84. PubMed ID: 22942186 [TBL] [Abstract][Full Text] [Related]
8. [HIT-LGG: effectiveness of carboplatin-vincristine in progressive low-grade gliomas of childhood--an interim report]. Gnekow AK; Kaatsch P; Kortmann R; Wiestler OD Klin Padiatr; 2000; 212(4):177-84. PubMed ID: 10994547 [TBL] [Abstract][Full Text] [Related]
9. Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. Packer RJ; Ater J; Allen J; Phillips P; Geyer R; Nicholson HS; Jakacki R; Kurczynski E; Needle M; Finlay J; Reaman G; Boyett JM J Neurosurg; 1997 May; 86(5):747-54. PubMed ID: 9126887 [TBL] [Abstract][Full Text] [Related]
11. Tolerance of nitrosurea-based multiagent chemotherapy regime for low-grade pediatric gliomas. Lancaster DL; Hoddes JA; Michalski A J Neurooncol; 2003 Jul; 63(3):289-94. PubMed ID: 12892235 [TBL] [Abstract][Full Text] [Related]
12. Management of chiasmal and hypothalamic gliomas of infancy and childhood with chemotherapy. Petronio J; Edwards MS; Prados M; Freyberger S; Rabbitt J; Silver P; Levin VA J Neurosurg; 1991 May; 74(5):701-8. PubMed ID: 1901597 [TBL] [Abstract][Full Text] [Related]
13. Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children's Cancer Group. Geyer JR; Sposto R; Jennings M; Boyett JM; Axtell RA; Breiger D; Broxson E; Donahue B; Finlay JL; Goldwein JW; Heier LA; Johnson D; Mazewski C; Miller DC; Packer R; Puccetti D; Radcliffe J; Tao ML; Shiminski-Maher T; J Clin Oncol; 2005 Oct; 23(30):7621-31. PubMed ID: 16234523 [TBL] [Abstract][Full Text] [Related]
14. Pediatric low-grade glioma and neurofibromatosis type 1: A single-institution experience. Ruggiero A; Attinà G; Campanelli A; Maurizi P; Triarico S; Romano A; Massimi L; Tamburrini G; Verdolotti T; Mastrangelo S J Cancer Res Ther; 2023; 19(2):228-234. PubMed ID: 37313902 [TBL] [Abstract][Full Text] [Related]
15. Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial. Fangusaro J; Onar-Thomas A; Young Poussaint T; Wu S; Ligon AH; Lindeman N; Banerjee A; Packer RJ; Kilburn LB; Goldman S; Pollack IF; Qaddoumi I; Jakacki RI; Fisher PG; Dhall G; Baxter P; Kreissman SG; Stewart CF; Jones DTW; Pfister SM; Vezina G; Stern JS; Panigrahy A; Patay Z; Tamrazi B; Jones JY; Haque SS; Enterline DS; Cha S; Fisher MJ; Doyle LA; Smith M; Dunkel IJ; Fouladi M Lancet Oncol; 2019 Jul; 20(7):1011-1022. PubMed ID: 31151904 [TBL] [Abstract][Full Text] [Related]
16. A pilot study using carboplatin, vincristine, and temozolomide in children with progressive/symptomatic low-grade glioma: a Children's Oncology Group study†. Chintagumpala M; Eckel SP; Krailo M; Morris M; Adesina A; Packer R; Lau C; Gajjar A Neuro Oncol; 2015 Aug; 17(8):1132-8. PubMed ID: 25854526 [TBL] [Abstract][Full Text] [Related]
17. Visual outcome of a cohort of children with neurofibromatosis type 1 and optic pathway glioma followed by a pediatric neuro-oncology program. Dalla Via P; Opocher E; Pinello ML; Calderone M; Viscardi E; Clementi M; Battistella PA; Laverda AM; Da Dalt L; Perilongo G Neuro Oncol; 2007 Oct; 9(4):430-7. PubMed ID: 17704361 [TBL] [Abstract][Full Text] [Related]
18. High-grade glioma in children under 5 years of age: a chemotherapy only approach with the BBSFOP protocol. Dufour C; Grill J; Lellouch-Tubiana A; Puget S; Chastagner P; Frappaz D; Doz F; Pichon F; Plantaz D; Gentet JC; Raquin MA; Kalifa C Eur J Cancer; 2006 Nov; 42(17):2939-45. PubMed ID: 16962317 [TBL] [Abstract][Full Text] [Related]
19. Phase II Weekly Vinblastine for Chemotherapy-Naïve Children With Progressive Low-Grade Glioma: A Canadian Pediatric Brain Tumor Consortium Study. Lassaletta A; Scheinemann K; Zelcer SM; Hukin J; Wilson BA; Jabado N; Carret AS; Lafay-Cousin L; Larouche V; Hawkins CE; Pond GR; Poskitt K; Keene D; Johnston DL; Eisenstat DD; Krishnatry R; Mistry M; Arnoldo A; Ramaswamy V; Huang A; Bartels U; Tabori U; Bouffet E J Clin Oncol; 2016 Oct; 34(29):3537-3543. PubMed ID: 27573663 [TBL] [Abstract][Full Text] [Related]
20. A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (≤16 years) low grade glioma - A final report. Gnekow AK; Walker DA; Kandels D; Picton S; Giorgio Perilongo ; Grill J; Stokland T; Sandstrom PE; Warmuth-Metz M; Pietsch T; Giangaspero F; Schmidt R; Faldum A; Kilmartin D; De Paoli A; De Salvo GL; Eur J Cancer; 2017 Aug; 81():206-225. PubMed ID: 28649001 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]